A5101295927- Diabetes Treatment and Management
- Frailty in Older Adults
- Nutrition and Health in Aging
- Medication Adherence and Compliance
- Gastric Cancer Management and Outcomes
- Healthcare Systems and Practices
- Phytoestrogen effects and research
- Bone Metabolism and Diseases
- Healthcare and Venom Research
- Retinal Diseases and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Metabolism, Diabetes, and Cancer
- Medicinal Plant Pharmacodynamics Research
- Retinal Development and Disorders
- Dementia and Cognitive Impairment Research
- Geriatric Care and Nursing Homes
- Diabetes Management and Research
- Ginkgo biloba and Cashew Applications
- Intensive Care Unit Cognitive Disorders
- Retinal Imaging and Analysis
Wuhan University
2024
Hubei University of Chinese Medicine
2024
Novo Nordisk (United States)
2024
Hangzhou Normal University
2024
Cairn University
2023
To investigate real-world treatment adherence and persistence in people with type 2 diabetes newly initiating oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or dipeptidyl peptidase-4 inhibitor (DPP-4i).
Exercise is effective in preventing frailty status older adults, but the effect of an exercise program based on Wellness Motivation Theory (WMT) status, self-efficacy for exercise, and quality life adults with pre-frailty remains unclear. Our objective was to examine efficacy a multicomponent WMT self-efficacy, among pre-frail adults.
Background: Given the scarcity of real-world evidence on long-term effectiveness, this study assessed effect a once-weekly injectable formulation semaglutide type 2 diabetes (sema OW T2D) HbA1c and weight outcomes in individuals with T2D. Methods: This retrospective database included adults T2D ≥7%, initiating sema from January 2018 to September 2021, using linked data IQVIA’s Longitudinal Prescription Claims, Professional Fee Ambulatory Electronic Medical Records US. Descriptive bivariate...
Introduction & Objective: Multiple clinical trials have shown cardiovascular benefits from glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D). This study describes persistence and adherence of once weekly (OW) GLP-1 RAs use by T2D atherosclerotic disease (ASCVD) a real-world setting. Methods: The used data the Optum Research Database 01 Jan 2017 through 28 Feb 2023 identified adult ASCVD ≥1 pharmacy claim for OW RAs. date first was index start...
Objective To investigate the effect of glucose transporter-1(GLUT1)suppression on microvasculature pathological changes in diabetic mice.Methods Thirty-six 8-week-old C57BL/6 mice were randomly divided into normal control,diabetic control and GLUT1 siRNA treatment groups.Diabetic model was established by intraperitoneal injection streptozotocin.GLUT1 group received intravitreal siRNA-mediated GLUT1,and other two groups equal amount non-specific siRNA.Twenty-one weeks after...